2023-05-10 17:37:31 ET
- Tenaya Therapeutics press release ( NASDAQ: TNYA ): Q1 GAAP EPS of -$0.43 beats by $0.15 .
- Cash and cash equivalents of $173.6M
- Research & Development (R&D) Expenses: R&D expenses for the quarter ended March 31, 2023, were $25.6 million. Non-cash stock-based compensation included in R&D expense was $1.6 million for the quarter ended March 31, 2023.
- General & Administrative (G&A) Expenses: G&A expenses for the quarter ended March 31, 2023, were $8.1 million. Non-cash stock-based compensation included in G&A expense was $1.9 million for the quarter ended March 31, 2023.
For further details see:
Tenaya Therapeutics GAAP EPS of -$0.43 beats by $0.15